GILD Stock UPDATES Gilead Sciences (GILD) 105.89 09/09/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Gilead Sciences (GILD) 105.89 $GILD

Final Glance: Biotechnology companies
AP - 43 mins ago
NEW YORK (AP) — Shares of some top biotechnology companies were down at the close of trading:

AstraZeneca Presents Unfavorable Benralizumab Study Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 2 hrs 23 mins ago
AstraZeneca (AZN) announced that data on its respiratory disease candidate, benralizumab, was published in The Lancet Respiratory Medicine.

Glaxo (GSK) Updates on Asthma Candidate Mepolizumab - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 2 hrs 38 mins ago
GlaxoSmithKline announced positive data from two pivotal phase III studies on its asthma candidate, mepolizumab.

Pluristem & United Therapeutics Progress with Phase I Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 09, 3:50PM CDT
Pluristem Therapeutics Inc. (PSTI) announced today that its licensee, United Therapeutics Corporation (UTHR), completed dosing of the first of the three cohorts of patients in a phase I study.

Hospira Down on Legal Blow; Court Allows Generic Precedex - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 09, 3:45PM CDT
Hosipra (HSP) suffered a setback with the court allowing the sale of generic Precedex.

Bayer Presents Positive Long-Term Results on Adempas - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 09, 3:25PM CDT
Bayer (BAYRY) announced positive results from long-term extension studies on Adempas.

Midday Glance: Biotechnology companies
AP - Tue Sep 09, 12:23PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 1 p.m.:

Early Glance: Biotechnology companies
AP - Tue Sep 09, 9:44AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 10 a.m.:

Critical Alerts For Gilead Sciences, Incyte Corp., Infinera Corporation, Ford and Pixelworks Released By InvestorsObserver
PR Newswire - Tue Sep 09, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for GILD, INCY, INFN, F and PXLW.

Global Infectious Disease Treatment Market 2014-2018: Key Vendors are F. Hoffmann-La Roche, Gilead Sciences, GSK, J&J Merck & Pfizer
M2 - Tue Sep 09, 3:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5tdjb4/global_infectious) has announced the addition of the "Global Infectious Disease Treatment Market 2014-2018" report to their offering. The analysts forecast the Global Infectious Disease Treatment market to grow at a CAGR of 3.43% over the period 2013-2018. Infectious diseases can be caused by various pathogenic microorganisms such as bacteria, fungi, parasites, or viruses. These diseases can be transmitted from one individual to another through either direct contact or indirect contact. Anti-infective drugs are used to kill (cidal) or stop the growth (static) of infectious agents. Based on the target organism, anti-infective drugs can be categorized into antibacterial, antiviral, antifungal, and antiparasitic. One of the emerging trends in this market is the emergence of Interferon-free regimens. Various all-oral, IFN-free regimens are under development and are expected to attain higher sustained virologic response and cause fewer side effects than the currently approved therapies. According to the report, the launch of Direct-acting Antivirals is one of the major drivers for the Global Infectious Disease Treatment market. DAAs are administered in combination with other antiviral drugs such as ribavirin and PEG-IFN and increase the efficacy of treatment and decrease the duration of therapy and this leads to increased preference for this treatment among patients. Further, the report states that a generic erosion of marketed drugs is one of the major challenges faced by the market. A loss of patent protection and market exclusivity generally triggers the entry of low-cost alternatives for drugs, which, in turn, decreases the sales of innovator-approved drugs. To calculate the market size, the report considers the revenue generated through the sales of various drugs administered to treat various infectious diseases caused by bacteria, virus, fungi, and parasites, which include: - Antibacterial drugs (beta-lactams, macrolides, aminoglycosides, phenicols, quinolones, sulfonamides, tetracyclines, and other antibacterials) - Antiviral drugs (HIV, hepatitis C, hepatitis B, and other antivirals) - Antifungal drugs (azoles, pyrimidines, echinodians, polyenes, allylamines, and other antifungal drugs) - Antiparasitic drugs Key Vendors - F. Hoffmann-La Roche - Gilead Sciences - GlaxoSmithKline - Johnson & Johnson - Merck - Pfizer For more information visit http://www.researchandmarkets.com/research/5t...infectious

Keryx Falls after Ferric Citrate's Approval with Warnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 5:05PM CDT
The FDA has approved Keryx's (KERX) ferric citrate to control serum phosphorus levels in patients suffering from CKD on dialysis.

OncoMed's Shares Gain on Lifting of Partial Clinical Hold - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 5:00PM CDT
OncoMed Pharmaceuticals' (OMED) shares were up 5.7% with the FDA lifting the partial clinical hold on ipafricept for ovarian cancer, pancreatic cancer and liver cancer.

Prana Biotechnology Up on Orphan Drug Status for PBT2 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 4:35PM CDT
The FDA has granted orphan drug designation to Prana Biotechnology's Huntington disease candidate, PBT2.

Novartis (NVS) Presents Positive Data on Ultibro Breezhaler - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 4:05PM CDT
Novartis (NVS) presented encouraging data on Ultibro Breezhaler from the LANTERN study at the European Respiratory Society (ERS) International Congress in Germany.

Bayer/Regeneron Looking for Eylea Label Expansion in Japan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 3:45PM CDT
Bayer submitted an MAA for Eylea in Japan for the treatment of patients suffering from macular edema secondary to BRVO.

Bristol-Myers Sues Merck of Patent Infringement on Keytruda - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 3:30PM CDT
Bristol-Myers (BMY) filed a patent infringement case against Merck (MRK).

Gilead Down on Likely Sovaldi Generic Deal in Poor Nations - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 2:39PM CDT
Gilead (GILD) is in talks with generic players on Sovaldi.

Pharmacyclics Price Target Cut On Higher Spending
at Investor's Business Daily - Mon Sep 08, 12:02PM CDT
Biotech Pharmacyclics (PCYC) got a price-target cut from Nomura on Monday, but the investment bank maintained a buy rating on Pharmacyclics stock, saying the company's competitive position remains strong. Pharmacyclics stock was flat in midday...

Atrial Fibrillation - Pipeline Review Report, H2 2014 - 15 Companies & 27 Drug Profiles
M2 - Mon Sep 08, 11:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xr5nbq/atrial) has announced the addition of the "Atrial Fibrillation - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Atrial Fibrillation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Atrial Fibrillation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - AstraZeneca PLC - Isis Pharmaceuticals, Inc. - Gilead Sciences, Inc. - Daiichi Sankyo Company, Limited - Nissan Chemical Industries, Ltd. - Laboratoires Pierre Fabre SA - Cardiome Pharma Corp - Xention Limited - HUYA Bioscience International, LLC - Milestone Pharmaceuticals, Inc. - Otsuka Holdings Co., Ltd. - Serodus ASA - Nyken BV - Armetheon, Inc. Drug Profiles - edoxaban tosylate - tecarfarin - vernakalant hydrochloride - bucindolol hydrochloride - vernakalant hydrochloride - ranolazine ER - XEN-D0103 - HBI-3000 - ISIS-CRPRx - (ranolazine dronedarone) - vanoxerine - F-373280 - BMS-919373 - XEN-D0101 - OPC-108459 - budiodarone - Small Molecule to Inhibit IKACh for Atrial Fibrillation - MSP-2017 - NYK-1112 - SER-102 - XEN-R0702 - GsMTx-4 - NIP-151 - Small Molecule to Block Kv1.5 for Atrial Fibrillation - Drug For Atrial Fibrillation - Small Molecule To Activate Heat Shock Protein 70 (Hsp70) For Post-Operative Atrial Fibrillation - Small Molecules to Inhibit Voltage Gated Sodium Channel for Atrial Fibrillation For more information visit http://www.researchandmarkets.com/research/xr5nbq/atrial




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sivers Semiconductors: Strategy Behind 2027 AGM Plans

Updated Category News Views 174

Setting the Stage for a Crucial Year Ah, the dance of corporate governance—an arena where maneuvering is an art. Sivers Semiconductors AB, a name that's becoming synonymous with innovation in the photonics and wireless solutions sector, is prepping for its 2027 Annual General Meeting. Ahead of this pivotal event, they're forming a Nomination Committee to shape future...

Continue Reading
ZTE Reinvents Energy for AI Data Centers

Updated Category News Views 127

The Great Race: Power and AI in Sync Here we are, neck-deep in the AI era, where the demand for raw computing power just won’t quit. With every data-hungry application and supercharged algorithm, companies are scrambling to keep up. But there’s a nasty little dragon in this fairy tale—energy efficiency. ZTE isn’t just acknowledging this beast; they’re ready to...

Continue Reading
Caregiving's Financial Impact on Women: Insights from Cinergy

Updated Category News Views 65

Women Caregivers Face Financial Crossroads When it comes down to it, caregiving is one heck of a responsibility, particularly for women. It's about the sacrifices they make, not just in time but in financial security, too. Step away from a job to care for someone, and it's a dicey game you're playing with future income. The Cost of Generosity: Financial Impacts Cindy...

Continue Reading
Elite Robots Expands Global Reach with Mobile Manipulators

Updated Category News Views 112

Robots Hitting the Road? Picture this: robots that aren't just bolted to a factory floor but roam the production lines like tireless workers on wheels. That's what Elite Robots is betting on with their shiny new ELITEMISSION mobile manipulators. Not Just Any Old Robot These bad boys combine a robotic arm with an autonomous mobile platform. Think of an octopus getting off...

Continue Reading
Ballard's Q3 2026: Navigating Losses and Bold Moves

Updated Category News Views 69

Ballard’s Financial Puzzles in Q3 2026 Riding the rough waters of the third quarter in 2026, Ballard Power Systems set out its stall with some eyebrow-raising numbers. This ain't the bustling diner vibe we normally see for a thriving business. The results paint a cautious picture sprinkled with strategic shifts that demand a keen eye. GeoPura Acquisition: A Strategic...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 252

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
Fluence Energy Faces Heat: Class Action Lawsuit Unfolds

Updated Category News Views 25

Fluence Energy's Difficult Waters Investors in Fluence Energy (NASDAQ: FLNC) are having a moment of reckoning, no doubt. November 2nd saw a nearly 9% drop in FLNC stock, further fueled by the sudden departures of the CEO and CFO just days earlier. This marks a bitter chapter for Fluence as its stock continues to bleed, leaving many wondering what seismic shifts are yet to...

Continue Reading
Nord Anglia Schools Shine with 13 Tes Awards Nominations

Updated Category News Views 7

Nord Anglia's Moment of Glory at Tes Awards You think you know the big players in the educational game? Well, guess again. Nord Anglia's come out swinging with a whopping 13 finalist nominations at the 2026 Tes Awards for International Schools. It ain't easy making waves in the education sector, but these folks are showing they've got what it takes to turn heads, not just...

Continue Reading
Ranger and Smith Unveil Tea-Infused Chocolate Bar

Updated Category News Views 11

Fresh Collaborations in Portland's Culinary Scene Ah, the sweet crossover in Portland's food scene is once again in the spotlight with a new entry that's sure to titillate taste buds. Ranger Chocolate Co. and Steven Smith Teamaker are at it again, rolling out a delectable creation that merges the poetic elegance of tea with the indulgent richness of chocolate. Welcome,...

Continue Reading
Palatin's Game-Changer: MC4R Agonist Hits the Stage

Updated Category News Views 62

Breaking New Ground in Obesity Treatment Palatin Technologies is stepping into the spotlight with some heavy ammunition in the fight against obesity. The company has just unveiled impressive preclinical data about their next-generation melanocortin-4 receptor (MC4R) agonists at the ObesityWeek® 2026 conference. This isn’t just your run-of-the-mill corporate...

Continue Reading

Top 5 Most Recently Viewed Articles

NVIDIA Set to Gain from Hyperscalers' Surge in AI Investments

Updated Category News Views 191

Massive Capital Expenditures Expected from Hyperscalers Recently, major hyperscalers have reported impressive third-quarter financial results, leading to significant updates regarding their capital expenditure (CapEx) plans as the AI market expands. Analysts are observing a dramatic increase in spending plans, with projections indicating that these companies might...

Continue Reading
JARS Cannabis Enhances Live Music Experience This Summer

Updated Category News Views 140

JARS Cannabis Expands Live Music Partnership The Michigan-based cannabis retailer, JARS Cannabis, is amplifying its engagement this summer by enhancing its partnership with 313 Presents. This strategic move aims to introduce a more vibrant presence at two of the region's iconic music venues: Pine Knob Music Theatre and the Michigan Lottery Amphitheatre at Freedom Hill....

Continue Reading
Significant Insights on Gender Differences in HoFH Research

Updated Category News Views 185

Groundbreaking Research Unveiled in Preventive Cardiology Journal The American Journal of Preventive Cardiology (AJPC) has published a groundbreaking study that delves into the crucial sex-based differences in homozygous familial hypercholesterolemia (HoFH). This pivotal research marks the first issue under the new leadership of Dr. Khurram Nasir as Editor-in-Chief and...

Continue Reading
Sugar Grove Ace Commemorates a Decade of Community Support

Updated Category News Views 90

Celebrate a Milestone: Sugar Grove Ace's 10th Anniversary Sugar Grove Ace is thrilled to celebrate its 10th anniversary with a community event that promises fun, excitement, and gratitude. This special gathering is set to take place on a Saturday in the near future, showcasing the store's dedication to its customers and the local community. Event Highlights The day will...

Continue Reading
Insightful Earnings Preview for Microvast Holdings (MVST)

Updated Category News Views 240

Understanding Microvast Holdings's Earnings Outlook Microvast Holdings (NASDAQ: MVST) is on the brink of releasing its next quarterly earnings report. Investors are eager to see how the company fares as speculation around performance intensifies. Let's delve into what to expect and the key indicators influencing stockholder sentiment. Earnings Expectations for the...

Continue Reading